Sugi Predict

Sugi Predict / Compounds / Fostedil

Fostedil

Fostedil

SCHEMBL612913

CCOP(=O)(Cc1ccc(-c2nc3ccccc3s2)cc1)OCC

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.53
▸ RAB9A P51151 6/20 0.53
▸ NPC1 O15118 5/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ PKM P14618 1/20 0.53
▸ MAPT P10636 4/20 0.52
▸ APP P05067 4/20 0.50
▸ GLA P06280 3/20 0.50
▸ GAA P10253 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ NOD2 Q9HC29 2/20 0.50
▸ MMP9 P14780 2/20 0.50
▸ MMP8 P22894 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ PAX8 Q06710 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ TNF P01375 1/20 0.50
▸ NOD1 Q9Y239 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fostedil SCHEMBL29387277 1.00 KDM4E (0.53) KDM4ERAB9ANPC1SMN1; SMN2PKM
SCHEMBL7407359 0.91 RAB9A (0.50) KDM4ERAB9ANPC1SMN1; SMN2PKM
SCHEMBL11160844 0.90 RAB9A (0.51) KDM4ERAB9ANPC1SMN1; SMN2PKM
Fostedil SCHEMBL11166196 0.89 RAB9A (0.46) KDM4ERAB9ANPC1SMN1; SMN2PKM
SCHEMBL10707569 0.89 RAB9A (0.54) KDM4ERAB9ANPC1SMN1; SMN2PKM
SCHEMBL11155474 0.88 ATP4A (0.57) KDM4ERAB9ANPC1SMN1; SMN2PKM
SCHEMBL7407470 0.88 F2RL3 (0.47) KDM4ERAB9ANPC1SMN1; SMN2PKM
SCHEMBL11153617 0.87 RAB9A (0.59) KDM4ERAB9ANPC1SMN1; SMN2PKM
SCHEMBL1984086 0.84 MAPT (0.55) KDM4ERAB9ANPC1SMN1; SMN2MAPT
SCHEMBL11159543 0.84 RAB9A (0.56) KDM4ERAB9ANPC1SMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002539162-A — — 2002-11-19 — — JP claimed
EP-1161238-A1 AMYOTROPIC LATERAL SCLEROSIS TREATMENT WITH A COMBINATION OF RILUZOLE AND AN AMPA RECEPTOR ANTAGONIST Aventis Pharma S.A. (FR) 2001-12-12 — — EP claimed
WO-2000054772-A1 AMYOTROPIC LATERAL SCLEROSIS TREATMENT WITH A COMBINATION OF RILUZOLE AND AN AMPA RECEPTOR ANTAGONIST AVENTIS PHARMA S.A. (FR) 2000-09-21 — — WO claimed
EP-0010120-B1 1-(BENZOTHIAZOL-2-YL)-4-DIALKOXYPHOSPHINYL METHYLBENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM KANEBO, LTD. (JP) 1983-03-02 — — EP claimed
US-4232010-A CARDIOTONIC AND HYPOTENSIVE AGENTS KANEBO, LTD. (JP) 1980-11-04 — — US claimed
EP-0010120-A1 1-(benzothiazol-2-yl)-4-dialkoxyphosphinyl methylbenzene derivatives and pharmaceutical compositions containing them KANEBO, LTD. (JP) 1980-04-30 — — EP claimed
JP-57150698-A — — None — — JP disclosed
JP-55105620-A — — None — — JP disclosed
EP-3004138-B1 ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME BAUSCH HEALTH IRELAND LTD (IE) 2024-03-13 — — EP disclosed
EP-4309673-A2 FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE Bausch Health Ireland Limited (IE) 2024-01-24 — — EP disclosed
US-20240002440-A1 AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS JPMORGAN CHASE BANK, N.A. 2024-01-04 — — US disclosed
US-11834521-B2 Ultra-pure agonists of guanylate cyclase C, method of making and using same BAUSCH HEALTH IRELAND LIMITED (IE) 2023-12-05 — — US disclosed
US-20230340023-A1 ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME JPMORGAN CHASE BANK, N.A. 2023-10-26 — — US disclosed
EP-0185132-A1 Novel ethyl benzylphosphinate derivatives, process for production thereof, and their use as calcium antagonist KANEBO, LTD. (JP) 1986-06-25 — — EP disclosed
US-4434162-A VASODILATOR, ANGINA PECTORIS, HYPOTENSIVE AGENTS KANEBO, LTD. (JP) 1984-02-28 — — US disclosed
EP-0010120-B1 1-(BENZOTHIAZOL-2-YL)-4-DIALKOXYPHOSPHINYL METHYLBENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM KANEBO, LTD. (JP) 1983-03-02 — — EP disclosed
JP-S57150698-A NOVEL 1-(BENZOTHIAZOL-2-YL)-4-DIETHOXY- OR DIISOPROPOXY- PHOSPHINYLBENZENE KANEBO LTD 1982-09-17 — — JP disclosed
US-4232010-A CARDIOTONIC AND HYPOTENSIVE AGENTS KANEBO, LTD. (JP) 1980-11-04 — — US disclosed
JP-S55105620-A CALCIUM ANTAGONIST KANEBO LTD 1980-08-13 — — JP disclosed
EP-0010120-A1 1-(benzothiazol-2-yl)-4-dialkoxyphosphinyl methylbenzene derivatives and pharmaceutical compositions containing them KANEBO, LTD. (JP) 1980-04-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230340023-A1 ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME GUCY1A1, GUCY1A2, GUCY1B1 KDM4E 1474/4885RAB9A 4060/4885NPC1 1062/4885
US-11834521-B2 Ultra-pure agonists of guanylate cyclase C, method of making and using same GUCY1A1, GUCY1A2, GUCY1B1 KDM4E 1474/4885RAB9A 4060/4885NPC1 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.